Review Article
Volume 12 Issue 2 - 2020
Transforming Curry Extract to Liposomal Curcumin (LipocurcTM) in Parkinson Disease (PD) Therapeutics Landscape: Emerging Role of Epigenetics Signaling and Nanotechnology
Simon S Chiu1,2*, Kristen Terpstra3, Michel Woodbury-Farina4, Ram Mishra5,6, Vladimir Badmaev7, Joshua T Varghese8, Hana Raheb1, Ed Lui9, Zack Cernovsky1, Yves Bureau1, Mariwan Husni10, John Copen11, Mujeeb Shad12, Hou Jirui13, Autumn Carriere1,14, Zahra Khazaeipool1,15, Robbie Campbell1 and Weam Sieffien16
1Department of Psychiatry, Western University (University of Western Ontario), Lawson Health Research Institute, London, Ontario, Canada
2Geriatric Mental Health Program, London Health Sciences Centre, Ontario, Canada
3Neurological Unit, St Michel’s Hospital Affiliated University, Toronto, Ontario, Canada
4Department of Psychiatry, School of Medicine, University of Puerto Rico, Puerto Rico
5Department of Psychiatry and Neurosciences, McMaster University School of Medicine, McMaster University Health Sciences Centre, Neuropharmacology Lab, Hamilton, Ontario, Canada
6Department of Medicine, School of Medicine, McMaster University Division of Neurology, Department of Clinical Neurological Sciences, Mc- Master University Health Sciences Centre, Hamilton, Ontario, Canada
7Medical Director, Medical Holdings Inc, New York, NY, USA
8Currently Year III Medical Student, Marian University College of Osteopathic Medicine, Indianapolis, Indiana, USA
9Department of Pharmacology, Western University, London, Ontario, Canada
10Department of Psychiatry, Northern Ontario Medical School, Thunderbay, Ontario, Canada
11Department of Psychiatry, University of Victoria Medical Campus, University of British Columbia, Victoria, BC, Canada
1212Department of Psychiatry, Oregon Health Sciences University, Portland, Oregon, USA
13Dalian Pharmaceutical Co. Natural Medicine Research and Development, Dalian Province, China
14Currently Nursing Program, Faculty Applied Sciences, Nipissing University, North Bay, ON, Canada
15Postdoctoral Research Fellow, University of Western Ontario, London, Ontario, Canada
16Currently Year III Medical Student, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
*Corresponding Author:Simon S Chiu, Geriatric Mental Health Program, London Health Sciences Centre, Ontario, Canada.
Received: December 30, 2019; Published: January 31, 2020




Abstract

Despite advances in genetics and brain imaging, none of the currently approved drugs for treatment of Parkinson Disease (PD) ranking second to Alzheimer Dementia Alzheimer Dementia (AD) the commonest neurodegenerative disorder, can modify the course of PD in terms of progressive functional decline. There is a paucity of data on the neurobiological underpinnings of prodromal phase of non-motor symptoms (NMS) of PD. Epigenetics signaling paradigm in probing genetics-environment interface comprises three components: DNA methylation, histone modification and non-coding RNA, in regulating expression of PD related genes. In PD, epigenomics plays an emerging pivotal role in shaping the impact of downstream cascade of dopamine neuronal loss, neuro-inflammation and oxidative stress in the basal ganglia and mesolimbic and mesocortical brain regions. We briefly review the current and emerging pharmaceutical treatment options for PD and related motor and NMS complications. We review the multi-faceted pharmacology of curry extract isolated from plant Curcuma Longata in translational models of PD, highlighting on the interplay of curcumin’s molecular footprints as epigenetics modulator interfacing differentially with alpha-Synuclein (SYN) and LRRK-2 Leucine-rich-repeat-kinase-2 (LRRK-2) mutation, the putative culprits in shaping the progressive course of PD. We briefly summarize the crucial milestones in transforming curcumin from curry extract to liposome-based curcumin: LipocurcTM via the navigating the challenging roadmap of nanotechnology. We summarize the pharmacokinetics data from Phase I trial of LipocurcTM exhibiting a highly favorable safety and tolerability profile of the potential PD drug lead. We conclude that both translational and clinical studies of curcumin serve as impetus for designing a transformative nanotechnology driven epigenetic-based PD therapeutics platform to the clinical arena. Accelerating biomarker-based clinical trials of LipocurcTM may the game-changer in PD therapeutics landscape.

Keywords: Curcumin; Parkinson Disease; Nanotechnology; Liposome; Epigenetics; Alpha-Synuclein (SYN) Leucine-Rich-Repeat-Kinase-2 (LRRK-2)

References

  1. Hye Mi Lee and Seong-Beom Koh. “Many Faces of Parkinson’s Disease: Non-Motor Symptoms of Parkinson’s Disease”. Journal of Movement Disorders 8.2 (2015): 92-97. 
  2. Dickson DW. “Neuropathology of Parkinson disease”. Parkinsonism and Related Disorders 46.1 (2018): S30-S33. 
  3. Thobois S., et al. “Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment”. Current Neurology and Neuroscience Reports 17.10 (2017): 76. 
  4. Strafella AP., et al. “Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers”. Movement Disorders 32.2 (2017): 181-192.  
  5. Fullard ME., et al. “Olfactory Dysfunction as an Early Biomarker in Parkinson's Disease”. Neuroscience Bulletin 33.5 (2017): 515-525.
  6. Burré J., et al. “Cell Biology and Pathophysiology of α-Synuclein”. Cold Spring Harbor Perspectives in Medicine 8.3 (2018). 
  7. Höglinger GU., et al. “A new dopaminergic nigro-olfactory projection”. Acta Neuropathologica 130.3 (2015): 333-348. 
  8. Domellöf ME., et al. “Olfactory dysfunction and dementia in newly diagnosed patients with Parkinson's disease”. Parkinsonism and Related Disorders 38 (2017): 41-47. 
  9. Fox SH., et al. “International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease”. Movement Disorders 33.8 (2018): 1248-1266. 
  10. Lang AE and Espay AJ. “Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations”. Movement Disorders 33.5 (2018): 660-677. 
  11. Connolly BS and Lang AE. “Pharmacological treatment of Parkinson disease: a review”. Journal of the American Medical Association 311.16 (2014): 1670-1683. 
  12. Fahn S Parkinson Study Group. “Does levodopa slow or hasten the rate of progression of Parkinson's disease?”. Journal of Neurology 252.4 (2005): IV37-IV42FAHN
  13. De Deurwaerdère P., et al. “Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry”. Progress in Neurobiology 151 (2017): 57-100. 
  14. Cova I and Priori A. “Diagnostic biomarkers for Parkinson's disease at a glance: where are we?”. Journal of Neural Transmission 125.10 (2018): 1417-1432. 
  15. Zhou CQ., et al. “Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease”. Journal of Clinical Neuroscience 21.7 (2014): 1094-1101. 
  16. Schaeffer E and Berg D. “Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease”. CNS Drugs 31.7 (2017): 551-570. 
  17. Sanford M and Scott LJ. “Rotigotine transdermal patch: a review of its use in the treatment of Parkinson's disease”. CNS Drugs 25.8 (2011): 699-719. 
  18. Wirdefeldt K., et al. “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review”. CNS Drugs 30.5 (2016): 381-404. 
  19. Unti E., et al. “Apomorphine hydrochloride for the treatment of Parkinson's disease”. Expert Review of Neurotherapeutics 15.7 (2015): 723-732. 
  20. Szökő É., et al. “Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease”. Journal of Neural Transmission 125.11 (2018): 1735-1749. 
  21. Hoy SM and Keating GM. “Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease”. Drugs 72.5 (2012): 643-669. 
  22. Binde CD., et al. “A multiple treatment comparison meta-analy29. sis of monoamine oxidase type B inhibitors for Parkinson's disease”. British Journal of Clinical Pharmacology 84.9 (2018): 1917-1927. 
  23. Blair HA and Dhillon S. “Safinamide: A Review in Parkinson's Disease”. CNS Drugs 31.2 (2017): 169-176. 
  24. Katsaiti I and Nixon J. “Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review”. Journal of Parkinson's Disease 8.2 (2018): 217-231. 
  25. Li J., et al. “Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis”. European Neurology 78.3-4 (2017): 143-153. 
  26. Leegwater-Kim J and Waters C. “Role of tolcapone in the treatment of Parkinson's disease”. Expert Review of Neurotherapeutics 7.12 (2007): 1649-1657. 
  27. Lees AJ., et al. “Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA”. Expert Review of Neurotherapeutics 17.7 (2017): 649-659. 
  28. Müller T and Möhr JD. “Recent Clinical Advances in Pharmacotherapy for Levodopa-Induced Dyskinesia”. Drugs 79.13 (2019): 1367-1374. 
  29. Paik J and Keam SJ. “Amantadine Extended-Release (GOCOVRI™): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease”. CNS Drugs 32.8 (2018): 797-806. 
  30. Sako W., et al. “The effect of estradefylline for Parkinson’s disease: A meta-analysis”. Scientific Reports 7.1 (2017): 18018. 
  31. Matsunaga S., et al. “Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis”. Journal of Alzheimer's Disease 56.4 (2017): 1229-1239. 
  32. Outeiro TF., et al. “LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?”. Biochemical Society Transactions 47.3 (2019): 827-838. 
  33. Pezzoli G and Cereda E. “Exposure to pesticides or solvents and risk of Parkinson disease”. Neurology 80.22 (2013): 2035-2041. 
  34. Shane V., et al. “The Epigenome as a therapeutic target for Parkinson's disease”. Neural Regeneration Research 11.11 (2016): 1735-1738. 
  35. Labbe C., et al. “Epigenetic regulation in Parkinson's disease”. Acta Neuropathologica 132 (2016): 515-530. 
  36. Masliah E., et al. “Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes”. Epigenetics 8 (2013): 1030-1038.
  37. Fernández-Santiago R., et al. “Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients”. EMBO Molecular Medicine 7.12 (2015): 1529-1546. 
  38. Tan YY., et al. “Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients”. Parkinsonism and Related Disorders 20.3 (2014): 308-313. 
  39. Ai SX., et al. “Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease”. Journal of the Neurological Sciences 337.1-2 (2014): 123-128. 
  40. Harrison IF and Dexter DT. “Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?”. Pharmacology and Therapeutics 140.1 (2013): 34-52. 
  41. Gebremedhin KG and Rademacher DJ. “Histone H3 acetylation in the postmortem Parkinson's disease primary motor cortex”. Neuroscience Letters 627 (2016): 121-125. 
  42. Park G., et al. “Regulation of Histone Acetylation by Autophagy in Parkinson Disease”. Journal of Biological Chemistry 291.7 (2016): 3531-3540.
  43. Izadpanah M., et al. “Potential of Extracellular Vesicles in Neurodegenerative Diseases: Diagnostic and Therapeutic Indications”. Journal of Molecular Neuroscience 66.2 (2018): 172-179. 
  44. Martinez B and Peplow PV. “MicroRNAs in Parkinson's disease and emerging therapeutic targets”. Neural Regeneration Research 12.12 (2017): 1945-1959. 
  45. Burgos K., et al. “Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology”. PLoS One. 9.5 (2014): e94839. 
  46. Bhat A Mahalakshmi AM., et al. “Benefits of curcumin in brain disorders”. BioFactors 45.5 (2019): 666-689. 
  47. Ji HF and Shen L. “The multiple pharmaceutical potential of curcumin in Parkinson's disease”. CNS and Neurological Disorders - Drug Targets 13.2 (2014): 369-373. 
  48. Maiti P and Dunbar GL. “Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases”. International Journal of Molecular Sciences 19.6 (2018): E1637.
  49. Boyanapalli SS and Tony Kong AN. “"Curcumin, the King of Spices”: Epigenetic Regulatory Mechanisms in the Prevention of Cancer, Neurological, and Inflammatory Diseases”. Current Pharmacology Reports 1.2 (2015): 129-139. 
  50. Wang XS., et al. “Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review”. BMC Complementary and Alternative Medicine 17.1 (2017): 412. 
  51. Tripanichkulwand Jaroensuppaperch E-O. “Ameliorating effects of curcumin on 6-0HDA- induced dopamine denervation, glial response and SOD1redu”. Scientific Reports 6 (2016): 28511. 
  52. Rajeswari A and Sabesan M. “Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice”. Inflammopharmacology 16 (2008): 96-99. 
  53. Jayaraj RL., et al. “CNB-001 a novel curcumin derivative, guards dopamine neurons in MPTP model of Parkinson's disease”. BioMed Research International (2014): 236182. 
  54. Chiu S., et al. “Liposomal- formulated curcumin [Lipocurc™] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform”. Journal of Complementary and Integrative Medicine (2013).
  55. Mochizuki H., et al. “A refined concept: α-synuclein dysregulation disease”. Neurochemistry International 119 (2018): 84-96. 
  56. Singh PK., et al. “Curcumin modulates α-synuclein aggregation and toxicity”. ACS Chemical Neuroscience 4.3 (2013): 393-407. 
  57. Jiang TF., et al. “Curcumin ameliorates the neurodegenerative pathology in A53T α-synuclein cell model of Parkinson's disease through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy”. Journal of Neuroimmune Pharmacology 8.1 (2013): 356-369. 
  58. Borghammer P. “How does Parkinson's disease begin? Perspectives on neuroanatomical pathways, prions, and histology”. Movement Disorders Journal 33.1 (2018): 48-57. 
  59. Breen DP., et al. “Gut-brain axis and the spread of α-synuclein pathology: Vagal highway or dead end?”. Movement Disorders 34.3 (2019): 307-316. 
  60. Sharma A., et al. “Constipation in Parkinson's Disease: a Nuisance or Nuanced Answer to the Pathophysiological Puzzle?”. Current Gastroenterology Reports 20.1 (2018): 1. 
  61. Ladner-Keay CL., et al. “A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds”. Prion 12.5-6 (2018): 280-300. 
  62. Limanaqi F., et al. “Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism”. International Journal of Molecular Science 20.13 (2019): E3274. 
  63. Teiten MH., et al. “Curcumin as a regulator of epigenetic events”. Molecular Nutrition and Food Research 57.9 (2013): 1619-1629. 
  64. Fu S and Kurzrock R. “Development of curcumin as an epigenetic agent”. Cancer 116.20 (2010): 4670-4676. 
  65. Vahid F., et al. “The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review”. Gene 562.1 (2015): 8-15.
  66. Hassan FU., et al. “Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects”. Frontiers in Genetics 10 (2019): 514. 
  67. Ganai SA., et al. “Modulating epigenetic HAT activity for reinstating acetylation homeostasis: A promising therapeutic strategy for neurological disorders”. Pharmacology and Therapeutics 166 (2016): 106-122. 
  68. Tang BL. “Sirtuins as modifiers of Parkinson's disease pathology”. Journal of Neuroscience Research 95.4 (2017): 930-942. 
  69. Chiu Simon., et al. “Exploratory Study of Curcumin isolated from Turmeric Curcuma Longa, the Putative Histone Deacetylase Inhibitor, as added-on strategy to antipsychotics in treating negative symptoms and Neuro-cognitive deficits in Schizophrenia”. Advance Research Journal of Multi-disciplinary Discoveries 40 (2015).
  70. Zendedel E., et al. “Impact of curcumin on sirtuins: A review”. Journal of Cellular Biochemistry 119.12 (2018): 10291-10300. 
  71. Bora-Tatar G., et al. “Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: activity and docking studies”. Bioorganic and Medicinal Chemistry 17 (2007): 5219-5228. 
  72. Genevieve P Delcuve., et al. “Davie Roles of histone deacetylases in epigenetic regulation: emerging paradigms from studies with inhibitors: review”. Clinical Epigenetics 4 (2012): 5. 
  73. St Laurent R., et al. “Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease”. Neuroscience 246 (2013): 382-390. 
  74. Geng L., et al. “miR-494-3p modulates the progression of in vitro and in vivo Parkinson's disease models by targeting SIRT3”. Neuroscience Letters 675 (2018): 23-30. 
  75. Pogue., et al. “Up-regulation of NF-kB-sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures”. Journal of Inorganic Biochemistry 105.11 (2011): 1434-1437. 
  76. Momtazi AA., et al. “Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases”. Molecular Diagnosis and Therapy 20.4 (2016): 335-345. 
  77. Kluss JH., et al. “LRRK2 links genetic and sporadic Parkinson's disease”. Biochemical Society Transactions 30 47.2 (2019): 651-661. 
  78. Chen ML and Wu RM. “LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review”. Journal of Biomedical Science 25.1 (2018): 52. 
  79. Outeiro TF Harvey K., et al. “LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders?”. Biochemical Society Transactions 47.3 (2019): 827-838. 
  80. Yang D., et al. “LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin”. Neurobiology of Disease 47.3 (2012): 385-392. 
  81. Ortiz-Ortiz MA., et al. “Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells”. Neuroscience Letters 468.2 (2010): 120-124. 
  82. Varghese Josh K., et al. “Differential expression of cerebral dopamine neurotrophic factor (CDNF) in the hippocampus and in the striatum of LRRK-2 mutant rat model of Parkinson’s disease”. International Conference in Parkinson Disease, Movement Disorders Journal 31 (2016). 
  83. Vau Nguyen AP and Moore DJ. “Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity”. Advances in Neurobiology 14 (2017): 71-88. 
  84. Han KA., et al. “Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation”. Human Molecular Genetics 26.1 (2017): 1-18. 
  85. Luerman GC., et al. “Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1”. Journal of Neurochemistry 128.4 (2014): 561-576. 
  86. Jamwal R. “Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers”. Journal of Integrative Medicine 16.6 (2018): 367-374. 
  87. Kunnumakkara AB., et al. “Is curcumin bioavailability a problem in humans: lessons from clinical trials”. Expert Opinion on Drug Metabolism and Toxicology 15.9 (2019): 705-733. 
  88. Chiu S., et al. “Intravenous Curcumin Distribution in the Rat Brain”. Journal of Anticancer Research 31.3 (2011): 907-912. 
  89. Yavarpour-Bali H., et al. “Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders”. International Journal of Nanomedicine 14 (2019): 4449-4460. 
  90. Helson L., et al. “Infusion pharmacokinetics of Lipocurc (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs”. Anticancer Research 32.10 (2012): 4365-4370. 
  91. Matabudul D., et al. “Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs”. Anticancer Research 32.10 (2012): 4359-4364. 
  92. Angela S., et al. “Safety, Tolerability and pharmacokinetics of liposomal curcumin (LipocurcTM) in healthy humans”. International Journal Clinical Pharmacology and Therapeutics 23 (2014): 1-12.
  93. Richard Greil., et al. “A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer Cancer”. Cancer Chemotherapy and Pharmacology 82.4 (2018): 695-706.
  94. Trompetero A., et al. “Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach”. Current Pharmaceutical Design 24.1 (2018): 22-45. 
  95. Goedert M and Neurodegeneration. “Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Aβ, tau, and α-synuclein”. Science 349.6248 (2015): 1255555. 
  96. Volpicelli-Daley L and Brundin P. “Prion-like propagation of pathology in Parkinson disease”. Handbook of Clinical Neurology 153 (2018): 321-335. 
  97. Zhong Z., et al. “Prion-like protein aggregates exploit the RHO GTPase to cofilin-1 signaling pathway to enter cells”. The EMBO Journal 37.6 (2018): e97822. 
  98. Caughey B., et al. “Inhibition of protease-resistant prion protein accumulation in vitro by curcumin”. Journal of Virology 77.9 (2003): 5499-5502. 
  99. Hafner-Bratkovic I., et al. “Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation”. Journal of Neurochemistry 104.6 (2008): 1553-1564.
  100. Riemer C., et al. “Evaluation of drugs for treatment of prion infections of the central nervous system”. Journal of General Virology 89 (2008): 594-597. 
Citation: Simon S Chiu., et al. “Transforming Curry Extract to Liposomal Curcumin (LipocurcTM) in Parkinson Disease (PD) Therapeutics Landscape: Emerging Role of Epigenetics Signaling and Nanotechnology”. EC Neurology 12.2 (2020): 01-24.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


August Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the August issue of respective journals and can be viewed in the current issue pages.

Submission Deadline for September Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the September issue of respective journals. Submissions are accepted on/before August 15, 2020.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk